logo

Protalix Biotherapeutics Inc. (PLX)



Trade PLX now with
  Date
  Headline
10/2/2020 8:13:27 AM Chiesi Global Rare Diseases And Protalix BioTherapeutics Announce Expanded Access Program For Pegunigalsidase Alfa
10/2/2020 8:02:41 AM Chiesi Global Rare Diseases, Protalix BioTherapeutics Launch Of An EAP In US For Pegunigalsidase Alfa For Fabry Disease
9/8/2020 7:02:58 AM Protalix Regains Compliance With NYSE American Continued Listing Standards
8/24/2020 6:53:31 AM Protalix Completes Treatment Period For Phase III BRIGHT Trial Of Pegunigalsidase Alfa For Treatment Of Fabry Disease
8/11/2020 6:51:55 AM Protalix BioTherapeutics, Chiesi Announce FDA Acceptance Of BLA For Pegunigalsidase Alfa
8/10/2020 6:52:28 AM Protalix BioTherapeutics Q2 Loss Per Share $0.13 Vs Loss $0.52 Last Year
6/8/2020 5:01:22 PM Protalix BioTherapeutics Appoints Yael Hayon As Its VP, Research And Development
6/1/2020 6:52:19 AM Protalix BioTherapeutics Q1 EPS $0.10 Vs Loss $0.50 Last Year
5/28/2020 6:52:08 AM Protalix BioTherapeutics Announces Submission Of BLA To FDA For Pegunigalsidase Alfa
5/11/2020 6:54:12 AM Protalix Reports Positive Topline Results From Phase III BRIDGE Clinical Trial Of PRX-102
3/16/2020 6:53:36 AM Protalix Agrees To Conduct Feasibility Study With Kirin On Production Of Novel Complex Protein
3/12/2020 8:07:45 AM Protalix BioTherapeutics Q4 Net Profit $0.3 Mln Or $0.02 Per Share
3/12/2020 7:59:26 AM Protalix BioTherapeutics Announces $43.7 Mln In Financing To Further Advance Its Programs In Fabry Disease